Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 3
1977 1
1978 1
1979 2
1980 1
1981 1
1982 1
1984 1
1985 2
1987 1
1988 1
1992 1
1993 2
1996 2
1999 1
2005 2
2007 2
2008 3
2010 1
2012 1
2013 3
2014 2
2015 4
2016 6
2017 3
2018 5
2019 3
2020 6
2021 2
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Abnormality of the alternative complement pathway"
Page 1
A Review of Complement Activation in SLE.
Weinstein A, Alexander RV, Zack DJ. Weinstein A, et al. Curr Rheumatol Rep. 2021 Feb 10;23(3):16. doi: 10.1007/s11926-021-00984-1. Curr Rheumatol Rep. 2021. PMID: 33569681 Free PMC article. Review.
C4d also is higher in patients with lupus nephritis. An elevated level of the alternative pathway split product, Bb, in early lupus pregnancy is a predictor of adverse outcomes in SLE patients with antiphospholipid antibodies. ...Both EC4d and PC4d are increa …
C4d also is higher in patients with lupus nephritis. An elevated level of the alternative pathway split product, Bb, in early …
Pathogenesis of Atypical Hemolytic Uremic Syndrome.
Yoshida Y, Kato H, Ikeda Y, Nangaku M. Yoshida Y, et al. J Atheroscler Thromb. 2019 Feb 1;26(2):99-110. doi: 10.5551/jat.RV17026. Epub 2018 Nov 2. J Atheroscler Thromb. 2019. PMID: 30393246 Free PMC article. Review.
Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure. aHUS is caused by uncontrolled complement activation in the alternative pathway (AP). A …
Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic hemoly …
C3G and Ig-MPGN-treatment standard.
Noris M, Remuzzi G. Noris M, et al. Nephrol Dial Transplant. 2024 Jan 31;39(2):202-214. doi: 10.1093/ndt/gfad182. Nephrol Dial Transplant. 2024. PMID: 37604793 Free PMC article. Review.
Primary C3G and Ig-MPGN share the same prevalence of low serum C3 levels and of abnormalities of the alternative pathway of complement, and patients who present a bioptic pattern of Ig-MPGN at onset may show a C3G pattern in a subsequent biopsy. ...We …
Primary C3G and Ig-MPGN share the same prevalence of low serum C3 levels and of abnormalities of the alternative pathway …
A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Schena FP, Esposito P, Rossini M. Schena FP, et al. Int J Mol Sci. 2020 Jan 14;21(2):525. doi: 10.3390/ijms21020525. Int J Mol Sci. 2020. PMID: 31947692 Free PMC article. Review.
The persistent presence of microhematuria with or without light or heavy proteinuria after an infection episode suggests the potential onset of C3 GP. These nephritides are characterized by abnormal activation of the complement alternative pathway, …
The persistent presence of microhematuria with or without light or heavy proteinuria after an infection episode suggests the potential onset …
C3 glomerulopathy and current dilemmas.
Ito N, Ohashi R, Nagata M. Ito N, et al. Clin Exp Nephrol. 2017 Aug;21(4):541-551. doi: 10.1007/s10157-016-1358-5. Epub 2016 Nov 23. Clin Exp Nephrol. 2017. PMID: 27878657 Free PMC article. Review.
C3 glomerulopathy (C3G) is a recently identified disease entity caused by dysregulation of the alternative complement pathway, and dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are its components. ...Recent molecular and genetic advances provid …
C3 glomerulopathy (C3G) is a recently identified disease entity caused by dysregulation of the alternative complement pathw …
l-ficolin-MASP arm of the complement system in schizophrenia.
Mayilyan KR, Krarup A, Soghoyan AF, Jensenius JC, Sim RB. Mayilyan KR, et al. Immunobiology. 2023 Mar;228(2):152349. doi: 10.1016/j.imbio.2023.152349. Epub 2023 Feb 15. Immunobiology. 2023. PMID: 36805857
The abnormal neurodevelopment secondary to in utero adversities, such as hypoxia, malnutrition and maternal infections, underlies schizophrenia (SZ) etiology. As the genes of MBL-associated serine proteases (MASP) of the complement lectin pathway, MASP1 and M …
The abnormal neurodevelopment secondary to in utero adversities, such as hypoxia, malnutrition and maternal infections, underlies sch …
Extra-renal manifestations of atypical hemolytic uremic syndrome.
Formeck C, Swiatecka-Urban A. Formeck C, et al. Pediatr Nephrol. 2019 Aug;34(8):1337-1348. doi: 10.1007/s00467-018-4039-7. Epub 2018 Aug 14. Pediatr Nephrol. 2019. PMID: 30109445 Free PMC article. Review.
Atypical hemolytic uremic syndrome (aHUS) is a rare and complex disease resulting from abnormal alternative complement activation with a wide range of clinical presentations. ...While some of these extra-renal manifestations occur in the acute phase of aHUS, …
Atypical hemolytic uremic syndrome (aHUS) is a rare and complex disease resulting from abnormal alternative complement …
Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?
Berentsen S, Barcellini W, D'Sa S, Jilma B. Berentsen S, et al. Immunotherapy. 2022 Oct;14(15):1191-1204. doi: 10.2217/imt-2022-0085. Epub 2022 Aug 10. Immunotherapy. 2022. PMID: 35946351 Review.
Sutimlimab, a monoclonal antibody that targets C1s, is the first complement inhibitor to be extensively studied in cold agglutinin disease. Sutimlimab selectively blocks the classical activation pathway and leaves the alternative and lectin pathways intact. T …
Sutimlimab, a monoclonal antibody that targets C1s, is the first complement inhibitor to be extensively studied in cold agglutinin di …
Genetic deficiencies of the complement system and association with disease--early components.
Kölble K, Reid KB. Kölble K, et al. Int Rev Immunol. 1993;10(1):17-36. doi: 10.3109/08830189309051169. Int Rev Immunol. 1993. PMID: 8340675 Review.
These observations are consistent with the current view of the complement system's role in handling immune complexes and combating microbial invasion. ...This concept is also supported by the primordial role of the alternative pathway in the evolution …
These observations are consistent with the current view of the complement system's role in handling immune complexes and comba …
Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.
De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. De Vriese AS, et al. J Am Soc Nephrol. 2015 Dec;26(12):2917-29. doi: 10.1681/ASN.2015020184. Epub 2015 Jul 16. J Am Soc Nephrol. 2015. PMID: 26185203 Free PMC article. Review.
Kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway (AP) are traditionally classified on the basis of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy appearance (de …
Kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway (AP) are traditionall …
65 results